Symbols

PHAT

Phathom·NASDAQ

--(--)

PHAT fundamentals

PHAT Q4 2025 Earnings

Phathom (PHAT) released its earnings on Feb 26, 2026: revenue was 57.58M (YoY +94.12%), beat estimates; EPS was -0.08 (YoY +92.38%), beat estimates.

Revenue / YoY

57.58M

+94.12%

EPS / YoY

-0.08

+92.38%

Report date

Feb 26, 2026

PHAT Earnings Call Summary for Q4,2025

Revenue Growth: 217% YoY increase to $175.1 million, driven by GI strategy and 1.1M prescriptions.
Capital Structure: Extended term loan maturity to 2029, reduced interest rate to 9.85%, and raised $130M via equity offering.
Sales Force Strength: 285/300 reps on board, 2,000+ top-tier GI adopters, and 64% Q4 scripts covered by insurance.
Competitive Position: Confident in VOQUEZNA's leadership despite second P-CAB entrant, with 65M GERD patients eligible for P-CABs.

Earnings

EPS

Revenue

Revenue & Expenses

PHAT has released its 2025 Q4 earnings report, with revenue of 57.58M, reflecting a YoY change of 94.12%, and net profit of -21.15M, showing a YoY change of 71.59%. The Sankey diagram below clearly presents PHAT's revenue sources and cost distribution.

Key Indicators

Phathom (PHAT) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Phathom (PHAT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Phathom (PHAT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Phathom (PHAT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown